Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn study sought better way to time eye injections

NCT ID NCT03435926

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if how well a person can fix their gaze relates to signs of active disease on eye scans in patients with age-related macular degeneration (ARMD) treated with antiVEGF injections. Researchers planned to follow patients for two years, measuring fixation quality and scan results at each visit. The goal was to improve when to give repeat injections. However, the study was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, it could help doctors decide when to retreat ARMD patients more precisely, potentially improving treatment timing.
What could go wrong
The study was withdrawn before enrolling anyone, so no results are available. It is unclear if the approach would work in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Feb 2018

Finished

Jan 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with active neovascular ARMD treated with antiVEGF

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients \> 50 years old, * With neovascular ARMD * who need an induction treatment (de novo patients or patients who had their last intravitreal injection of antiVEGF more than 6 months ago) Exclusion Criteria: * Other maculopathies * Severe glaucoma with central visual field defect * Diabetic patients * Corneal, lens or vitreous opacities interfering in OCT analysis * Attention or comprehension deficit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroidal neovascularization, visual field, visual acuity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

choroidal neovascularization wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroidal neovascularization, visual field, visual acuity

Contacts and locations

Locations

  • University Hospital

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.